China Urges Firms Not to Use Nvidia H20 Chips In New Guidance
Over the past few weeks, Chinese authorities have sent notices to a range of firms discouraging use of the less-advanced semiconductors, people familiar with the matter said, asking not to be named discussing sensitive information. The guidance was particularly strong against the use of H20s for any government or national security-related work by state enterprises or private companies, the people said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Crypto is having a breakout summer — and bitcoin isn't the reason: Morning Brief
Riding high from a series of legislative wins and a wave of new financial initiatives, crypto investors are on the up and up. Another blast of positive catalysts has given the crypto world even more room to run this week. And most notably, the big news items don't really involve bitcoin. Circle (CRCL), the issuer of the second-largest stablecoin, posted better-than-expected quarterly revenue for the first time since going public. Bitmine (BMNR), an Ethereum treasury company, announced plans to sell up to another $20 billion worth of stock to boost its holdings of the cryptocurrency. And an array of popular altcoins are gaining ground. The moves collectively reflect the warm embrace of the Trump administration, which has championed the crypto industry and shifted the regulatory environment long seen as an obstacle to the adoption and growth of digital currency. But the success of Wall Street's crypto hedges also underscores rising institutional interest. Despite the risks, and perhaps because of them, more investors are growing comfortable with crypto exposure. And companies are chasing the returns of amassing tokens in a feedback loop that, however fleeting and precarious, seems to be paying off. Sign up for the Yahoo Finance Morning Brief By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Home to the fastest-growing major stablecoin over the past year, Circle shares are up more than 400% from its IPO price of $31 per share. As our colleague Ines Ferré reported, the company has been at the center of optimism over the stablecoin market following the passage of the GENIUS Act, legislation that creates a framework for digital tokens backed by assets such as the US dollar. Circle makes much of its money from interest income, specifically from short-term Treasury bills backing its stablecoin, USDC. After announcing a new blockchain network for stablecoin finance on Tuesday, shares rose another 3%. It's a play that could deliver some of crypto's promise for innovation to the financial services industry, and Wall Street and investors are paying attention — and making sure they're involved. Bitmine's surge highlights another pillar of crypto's ascendance in the financial world: the rise of crypto treasury companies. Riffing off the playbook of Strategy (MSTR), which sells new shares and debt to buy and hold more bitcoin, other players are finding success by accumulating other currencies, like ethereum. Bitmine, whose board is led by investor Tom Lee, announced this week that its holdings of ETH now account for roughly 1% of all tokens in circulation, sending the stock up more than 14%. The company's goal is to eventually reach 5% of the world's outstanding ETH tokens. Shares have surged over 600% this year. As this newsletter has written recently, the crypto accumulation strategy isn't working for every imitator, but it does work, as bitcoin continues to climb. But it's not just the dominant tokens that are gaining steam. Over the past week, the 10 largest digital currencies, according to data from CoinMarketCap, have gained. As our colleague Jake Conley reported, Ripple ( and Chainlink (LINK-USD) are among the altcoins rallying, fueled by an acquisition of a payment platform and the launch of a token reserve, respectively. The heady action seems far removed from the crypto winters of the past. But if this is the dawn of a new financial system, as crypto bulls like to profess, this summer is making it a lot easier to make that case. Hamza Shaban is a reporter for Yahoo Finance covering markets and the economy. Follow Hamza on X @hshaban. Click here for in-depth analysis of the latest stock market news and events moving stock prices
Yahoo
25 minutes ago
- Yahoo
Fatface to close all US stores and to focus on digital operations
Fashion chain Fatface is set to close all 23 of its stores in the US, transitioning its North American operations entirely to online. Media reports indicate that escalating operational expenses and economic headwinds are the primary reasons for moving away from brick-and-mortar outlets. Fatface CEO Will Crumbie was quoted by Express as saying: "While with any digital migration it can take time, this move will give us additional digital capabilities to enhance the experience for our customers and more seamlessly manage our operations." FatFace operates a network of more than 191 stores in the UK, six in the Republic of Ireland and 20 locations in the US and Canada, alongside a robust social media presence. In 2023, the brand was incorporated into Next. Meanwhile, Fatface is expanding its footprint in the UK market by inaugurating three new stores, renovating seven and refreshing the facades of 28 others during 2025. The B Corp-certified [indicating high social and environmental performance, transparency and accountability standards, verified by the non-profit network B Lab] company also plans to venture into additional international markets via its digital platform soon. In March 2025, FatFace announced that it had improved its B Corp score from 80.4 to 89.1 following a recertification process. "Fatface to close all US stores and to focus on digital operations" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
